Positron-emission tomography in gynaecologic malignancies

Archives of Gynecology and Obstetrics

Volumn 280, Issue 4, 2009, Pages 521-528

  Maffione, Anna Margherita ^a   Piva, Michela ^a   Tsamita, Charoula Stavroula ^a   Nanni, Cristina ^a   Castellucci, Paolo ^a   Ambrosini, Valentina ^a   Lopci, Egesta ^a   Musto, Alessandra ^a   Rampin, Lucia ^b   Grassetto, Gaia ^b   Marzola, Maria Cristina ^b   Massaro, Arianna ^b   Cracco, Elena ^c   Al Nahhas, Adil ^d   Fanti, Stefano ^a   Rubello, Domenico ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c Ospedale Umberto I   (Italy)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cervical cancer; Endometrial cancer; Gynaecologic malignancy; Oncology; Ovarian cancer; PET CT

Indexed keywords

CA 125 ANTIGEN; CHOLINE C 11; FLUORODEOXYGLUCOSE F 18;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISTANT METASTASIS; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HUMAN; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; REVIEW; RISK FACTOR; THREE DIMENSIONAL IMAGING; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERUS SARCOMA; VULVA CARCINOMA;

CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; GENITAL NEOPLASMS, FEMALE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; SARCOMA; SENSITIVITY AND SPECIFICITY;

EID: 69249248095     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-0979-2     Document Type: Review

References (41)

1. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf
2. RT Greenlee T Murray S Bolden PA Wingo 2000 Cancer statistics 2000 CA Cancer J Clin 50 7 33 10.3322/canjclin.50.1.7
3. Hacker NF (2000) Vulvar cancer. In: Berek JS, Hacker NF (eds) Practical gynaecologic oncology, 3. Williams & Wilkins, Baltimore, pp 553-596
4. PV Loar III RK Reynolds 2007 Sentinel lymph node mapping in gynecologic malignancies Int J Gynaecol Obstet 99 69 74 10.1016/j.ijgo.2007.06.001 (Pubitemid 47348001)
5. J Hauspy M Beiner I Harley L Ehrlich G Rasty A Covens 2007 Sentinel lymph node in vulvar cancer Cancer 110 5 1015 1023 10.1002/cncr.22874 (Pubitemid 47312867)
6. DE Cohn F Dehdashti RK Gibb DG Mutch JS Rader BA Siegel TJ Herzoq 2002 Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer Gynecol Oncol 85 179 184 10.1006/gyno.2002.6605 (Pubitemid 34304031)
7. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108
8. N Pandit-Taskar 2005 Oncologic imaging in gynecologic malignancies J Nucl Med 46 1842 1850
9. M Plummer S Franceschi 2000 Strategies for HPV prevention Virus Res 89 285 293 10.1016/S0168-1702(02)00197-1
10. JP Baak EC Wisse-Brekelmans FA Langley A Talerman JF Delemarre 1986 Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours J Clin Pathol 39 1340 1346 10.1136/jcp.39.12.1340
11. S Fanti C Nanni V Ambrosini MD Gross D Rubello M Farsad 2007 PET in genitourinary tract cancers Q J Nucl Med Mol Imaging 51 260 271
12. TZ Wong EL Jones RE Coleman 2004 Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-d-glucose for evaluating local and distant disease in patients with cervical cancer Mol Imaging Biol 6 55 62 10.1016/j.mibio.2003.12. 004 (Pubitemid 38240359)
13. JW Roh SS Seo S Lee RW Kang SK Kim JS Sim JY Kim EK Hong DS Cho JS Lee SY Park 2005 Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: a prospective surgicopathologic correlation study Eur J Cancer 41 2086 2092 10.1016/j.ejca.2005.05.013 (Pubitemid 41337950)
14. JD Wright F Dehdashti TJ Herzog DG Mutch PC Huettner JS Rader RK Gibb MA Powell F Gao BA Siegel PW Grisby 2005 Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-d-glucose-positron emission tomography Cancer 104 2484 2491 10.1002/cncr.21527 (Pubitemid 41691572)
15. HJ Choi JW Roh SS Seo S Lee JY Kim SK Kim KW Kang JS Lee JY Jeong SY Park 2006 Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study Cancer 106 914 922 10.1002/cncr.21641 (Pubitemid 43238460)
16. S Sironi A Buda M Picchio P Perego R Moreni A Pellegrino M Colombo C Mangioni C Messa F Fazio 2006 Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT Radiology 238 272 279 10.1148/radiol.2381041799 (Pubitemid 43010605)
17. TC Yen CH Lai SY Ma KG Huang HJ Huang JH Hong S Hsueh WJ Lin KK Nq TC Chang 2006 Comparative benefits and limitations of (18)F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer Eur J Nucl Med Mol Imaging 33 1399 1407 10.1007/s00259-006-0090-x (Pubitemid 44885405)
18. HH Chung H Jo WJ Kang JW Kim NH Park YS Song JK Chung SB Kang HP Lee 2007 Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence Gynecol Oncol 104 529 534 10.1016/j.ygyno.2006.09.009 (Pubitemid 46240239)
19. TC Yen LC See TC Chang KG Huang KK Ng SG Tang YC Chang S Hsueh CS Tsai CH Lai 2004 Defining the priority of using 18F-FDG PET for recurrent cervical cancer J Nucl Med 45 1632 1639
20. JK Schwarz BA Siegel F Dehdashti PW Grigsby 2007 Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma J Am Med Assoc 298 2289 2295 10.1001/jama.298.19.2289 (Pubitemid 350146219)
21. K Kitajima K Murakami E Yamasaki I Fukasawa N Inaba Y Kaji K Sugimura 2008 Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer AJR Am J Roentgenol 190 1652 1658 10.2214/AJR.07.3372 (Pubitemid 351798544)
22. D Nayot JS Kwon MS Carey A Driedger 2008 Does preoperative positron emission tomography with computed tomography predict nodal status in endometrial cancer? A pilot study Curr Oncol 15 123 125
23. HH Chung WJ Kang JW Kim NH Park YS Song JK Chung SB Kang 2008 The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings Eur J Nucl Med Mol Imaging 35 1081 1088 10.1007/s00259-007-0687-8
24. M Murakami H Tsukada M Shida M Watanabe H Maeda S Koido 2006 Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas Int J Gynecol Cancer 16 854 860 10.1111/j.1525-1438.2006.00532.x
25. JY Park EN Kim DY Kim DS Suh JH Kim YM Kim YT Kim JH Nam 2008 Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma Gynecol Oncol 109 255 262 10.1016/j.ygyno.2008.01.030
26. PL Sung YJ Chen RS Liu HJ Shieh PH Wang MS Yen KC Wen SH Shen CR Lai CC Yuan 2008 Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas Eur J Gynaecol Oncol 29 246 251
27. LH Smith 2006 Early clinical detection of ovarian cancer: a review of the evidence Expert Rev Anticancer Ther 6 1045 1052 10.1586/14737140.6.7.1045 (Pubitemid 44203382)
28. American Cancer Society Cancer facts and figures: 1998 (1998) American Cancer Society, Atlanta, GA, 13
29. DG Bragg 1993 Imaging in gynecologic malignancies Cancer 71 1648 1651
30. Y Yoshida T Kurokawa K Kawahara A Yagihara T Tsuchida H Okazawa 2004 Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer AJR Am J Roentgenol 182 227 233
31. P Castellucci AM Perrone M Picchio T Ghi M Farsad C Nanni C Messa MC Meriggiola G Pelusi A Al-Nahhas D Rubello F Fazio S Fanti 2007 Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology Nucl Med Commun 28 589 595 10.1097/MNM.0b013e3281afa256 (Pubitemid 47067045)
32. K Kitajima K Murakami E Yamasaki Y Kaji I Fukasawa N Inaba K Sugimura 2008 Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT Eur J Nucl Med Mol Imaging 35 1912 1920 10.1007/s00259-008-0890-2
33. N Avril S Sassen B Schmalfeldt J Naehrig S Rutke WA Weber 2005 Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer J Clin Oncol 23 7445 7453 10.1200/JCO.2005.06.965 (Pubitemid 46291806)
34. LJ Havrilesky SL Kulasingam DB Matchar ER Myers 2005 FDG-PET for management of cervical and ovarian cancer Gynecol Oncol 97 183 191 10.1016/j.ygyno.2004.12.007 (Pubitemid 40403692)
35. D Delbeke WH Martin 2001 Positron emission tomography imaging in oncology Radiol Clin North Am 39 883 917 10.1016/S0033-8389(05)70319-5 (Pubitemid 32912034)
36. C Nanni D Rubello M Farsad P De Iaco M Sansovini P Erba L Rampin G Mariani S Fanti 2005 (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients Eur J Surg Oncol 31 792 797 10.1016/j.ejso.2005.02.029 (Pubitemid 41194659)
37. M Takekuma M Maeda T Ozawa K Yasumi T Torizuka 2005 Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer Int J Clin Oncol 10 177 181 10.1007/s10147-005-0489-6 (Pubitemid 40933691)
38. 18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma Eur Radiol 10 761 767 10.1007/s003300051000 (Pubitemid 30321087)
39. C Menzel N Dobert N Hamscho K Zaplatnikov S Vasvatekis V Matic 2004 The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer Strahlenther Onkol 180 8 497 501 10.1007/s00066-004-1208-3
40. T Torizuka T Kanno M Futatsubashi H Okada E Yoshikawa F Nakamura M Takekuma M Maeda Y Ouchi 2003 Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET J Nucl Med 44 1051 1056
41. AA Van der Veldt G Luurtsema M Lubberink AA Lammertsma NH Hendrikse 2008 Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance Curr Pharm Des 14 28 2914 2931 10.2174/138161208786404344